Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT

Anti-thymocyte globulin (ATG) is widely used to prevent graft-versus-host disease (GVHD) after allogeneic peripheral blood stem cell transplantation (alloPBSCT). The goal of this study was to retrospectively assess the effect of ATG on outcomes in the setting of Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+  ALL).

Source: European Journal of Cancer - December 5, 2018 Category: Cancer & Oncology Authors: Sebastian Giebel, Myriam Labopin, Tomasz Czerw, G érard Socié, Didier Blaise, Ardeshir Ghavamzadeh, Jacob Passweg, Per Ljungman, Xavier Poiré, Patrice Chevallier, Péter Reményi, Alessandro Rambaldi, Boris Anafasyev, Nathalie Fegueux, Montserrat Rovir Tags: Original Research Source Type: research